Biosimilar Monoclonal Antibodies Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2023

  • ID: 4459981
  • Report
  • Region: Global
  • 100 pages
  • Infinium Global Research
1 of 4

FEATURED COMPANIES

  • Allergan plc.
  • BIOCAD
  • Biocon
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim GmbH
  • Celltrion, Inc.
  • MORE
The report on global biosimilar monoclonal antibodies market provides qualitative and quantitative analysis for the period of 2015 to 2023. The report predicts the global biosimilar monoclonal antibodies market to grow with a CAGR of 42.8% over the forecast period of 2017-2023. The study on biosimilar monoclonal antibodies market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific and RoW for the period of 2015 to 2023.

The report on biosimilar monoclonal antibodies market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global biosimilar monoclonal antibodies market over the period of 2015 to 2023. Moreover, the report is collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global biosimilar monoclonal antibodies market over the period of 2015 to 2023. Further, the Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.

Research Methodology

Primary Research

Primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through:

1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from LinkedIn, Hoovers, Factiva and Bloggers

Primary research respondents typically include:
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.

Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global biosimilar monoclonal antibodies market is segmented on the basis of drug class and application.

Global Biosimilar Monoclonal Antibodies Market by Drug Class
  • Rituximab
  • Infliximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab
Global Biosimilar Monoclonal Antibodies Market by Application
  • Oncology
  • Chronic And Autoimmune Diseases
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Others
Global Biosimilar Monoclonal Antibodies Market by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Rest of the World
Company Profiles
  • Pfizer, Inc.
  • Novartis AG
  • Reliance Life Sciences
  • Allergan plc.
  • Coherus BioSciences
  • Biocon
  • Dr. Reddy's Laboratories Ltd.
  • Boehringer Ingelheim GmbH
  • BioXpress Therapeutics SA
  • Intas Pharmaceuticals Limited
  • BIOCAD
  • Genor BioPharma Co. Ltd
  • Celltrion, Inc.
How this report delivers?
1. Comprehensive analysis of global as well as regional markets of biosimilar monoclonal antibodies market.
2. Complete coverage of all the segments in biosimilar monoclonal antibodies market to analyze the trends, developments in the global market and forecast of market size up to 2023.
3. Comprehensive analysis of the companies operating in global biosimilar monoclonal antibodies market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. The Growth Matrix presents analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan plc.
  • BIOCAD
  • Biocon
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim GmbH
  • Celltrion, Inc.
  • MORE
1. Report Overview
1.1 Report Description
1.2 Research Methods
1.3 Research Approaches

2. Executive Summary

3. Biosimilar Monoclonal Antibodies Market Overview
3.1 Introduction
3.2 Market Dynamics
3.3 Drivers
3.4 Restraints
3.5 Opportunities
3.6 Challenges
3.7 Porter’s Five Forces Analysis
3.8 Growth Matrix Analysis
3.9 Competitive Landscape in the Biosimilar Monoclonal Antibodies Market

4. Global Biosimilar Monoclonal Antibodies Market, by Drug Class, (USD Million) 2015 - 2023
4.1 Introduction
4.2 Rituximab
4.3 Infliximab
4.4 Abciximab
4.5 Trastuzumab
4.6 Adalimumab
4.7 Bevacizumab

5. Global Biosimilar Monoclonal Antibodies Market, by Application, (USD Million) 2015 - 2023
5.1 Introduction
5.2 Oncology
5.3 Chronic and Autoimmune Diseases
5.4 Growth Hormone Deficiency
5.5 Infectious Diseases
5.6 Others

6. Global Biosimilar Monoclonal Antibodies Market, by Region, (USD Million) 2015 - 2023
6.1 Introduction
6.2 North America
6.2.1 North America Biosimilar Monoclonal Antibodies Market, by Drug Class (USD Million)
6.2.2 North America Biosimilar Monoclonal Antibodies Market, by Application (USD Million)
6.3 Europe
6.3.1 Europe Biosimilar Monoclonal Antibodies Market, by Drug Class (USD Million)
6.3.2 Europe Biosimilar Monoclonal Antibodies Market, by Application (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Biosimilar Monoclonal Antibodies Market, by Drug Class (USD Million)
6.4.2 Asia Pacific Biosimilar Monoclonal Antibodies Market, by Application (USD Million)
6.5 Latin America
6.5.1 Latin America Biosimilar Monoclonal Antibodies Market, by Drug Class (USD Million)
6.5.2 Latin America Biosimilar Monoclonal Antibodies Market, by Application (USD Million)
6.6 Rest of the World
6.6.1 RoW Biosimilar Monoclonal Antibodies Market, by Drug Class (USD Million)
6.6.2 RoW Biosimilar Monoclonal Antibodies Market, by Application (USD Million)

7. Leading Companies
7.1 Company Profiles
7.1.1 Pfizer, Inc.
7.1.2 Novartis AG
7.1.3 Reliance Life Sciences
7.1.4 Allergan plc
7.1.5 Coherus BioSciences, Inc.
7.1.6 Biocon
7.1.7 Dr. Reddy's Laboratories Ltd.
7.1.8 Boehringer Ingelheim GmbH
7.1.9 BioXpress Therapeutics SA
7.1.10 Intas Pharmaceuticals Limited
7.1.11 BIOCAD
7.1.12 Genor BioPharma Co. Ltd
7.1.13 Celltrion, Inc.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer, Inc.
  • Novartis AG
  • Reliance Life Sciences
  • Allergan plc.
  • Coherus BioSciences
  • Biocon
  • Dr. Reddy's Laboratories Ltd.
  • Boehringer Ingelheim GmbH
  • BioXpress Therapeutics SA
  • Intas Pharmaceuticals Limited
  • BIOCAD
  • Genor BioPharma Co. Ltd
  • Celltrion, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll